Suppr超能文献

人类肺癌中转录因子 DP1 和 CTNND1 的基因扩增。

Gene amplification of the transcription factor DP1 and CTNND1 in human lung cancer.

机构信息

Genes and Cancer Group, Programa de Epigenetica y Biologia del Cancer (PEBC), Institut d'Investigacions Biomediques Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.

出版信息

J Pathol. 2010 Sep;222(1):89-98. doi: 10.1002/path.2732.

Abstract

The search for novel oncogenes is important because they could be the target of future specific anticancer therapies. In the present paper we report the identification of novel amplified genes in lung cancer by means of global gene expression analysis. To screen for amplicons, we aligned the gene expression data according to the position of transcripts in the human genome and searched for clusters of over-expressed genes. We found several clusters with gene over-expression, suggesting an underlying genomic amplification. FISH and microarray analysis for DNA copy number in two clusters, at chromosomes 11q12 and 13q34, confirmed the presence of amplifications spanning about 0.4 and 1 Mb for 11q12 and 13q34, respectively. Amplification at these regions each occurred at a frequency of 3%. Moreover, quantitative RT-PCR of each individual transcript within the amplicons allowed us to verify the increased in gene expression of several genes. The p120ctn and DP1 proteins, encoded by two candidate oncogenes, CTNND1 and TFDP1, at 11q12 and 13q amplicons, respectively, showed very strong immunostaining in lung tumours with gene amplification. We then focused on the 13q34 amplicon and in the TFDP1 candidate oncogene. To further determine the oncogenic properties of DP1, we searched for lung cancer cell lines carrying TFDP1 amplification. Depletion of TFDP1 expression by small interference RNA in a lung cancer cell line (HCC33) with TFDP1 amplification and protein over-expression reduced cell viability by 50%. In conclusion, we report the identification of two novel amplicons, at 13q34 and 11q12, each occurring at a frequency of 3% of non-small cell lung cancers. TFDP1, which encodes the E2F-associated transcription factor DP1 is a candidate oncogene at 13q34. The data discussed in this publication have been deposited in NCBIs Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/) and are accessible through GEO Series Accession No. GSE21168.

摘要

寻找新的癌基因很重要,因为它们可能成为未来特定抗癌疗法的靶点。在本文中,我们报告了通过全局基因表达分析鉴定肺癌中的新扩增基因。为了筛选扩增子,我们根据转录本在人类基因组中的位置对基因表达数据进行了比对,并搜索了过表达基因的聚类。我们发现了几个基因过表达的聚类,提示存在潜在的基因组扩增。在两个聚类(染色体 11q12 和 13q34)中进行了 FISH 和微阵列分析以检测 DNA 拷贝数,证实了分别跨越约 0.4 和 1 Mb 的 11q12 和 13q34 扩增的存在。这两个区域的扩增频率均为 3%。此外,对扩增子内每个基因的定量 RT-PCR 允许我们验证多个基因表达增加。在具有基因扩增的肺癌肿瘤中,p120ctn 和 DP1 蛋白,分别由两个候选癌基因 CTNND1 和 TFDP1 编码,在 11q12 和 13q 扩增子中显示出非常强的免疫染色。然后,我们将重点放在 13q34 扩增子和 TFDP1 候选癌基因上。为了进一步确定 DP1 的致癌特性,我们搜索了携带 TFDP1 扩增的肺癌细胞系。在具有 TFDP1 扩增和蛋白过表达的肺癌细胞系(HCC33)中,通过小干扰 RNA 耗尽 TFDP1 表达使细胞活力降低了 50%。总之,我们报告了两个新的扩增子的鉴定,分别位于 13q34 和 11q12,非小细胞肺癌的发生频率均为 3%。TFDP1 编码 E2F 相关转录因子 DP1,是 13q34 的候选癌基因。本文讨论的数据已被存入 NCBI 的基因表达综合数据库(GEO;http://www.ncbi.nlm.nih.gov/geo/),并可通过 GEO 系列访问号 GSE21168 获得。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验